Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

209

HTML

1875

Figures (1-2)

170

Tables (1-2)

138

Sum=2392

Jun 15, 2003 (publication date) through Nov 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Jun 15, 2003; 9(6): 1374-1376
Published online Jun 15, 2003. doi: 10.3748/wjg.v9.i6.1374

Figure 1 The overall survival rates for clinical T_1-2 esophageal carcinoma treated with LCAF radiotherapy.

Figure 2 The local control rates for clinical T_1-2 esophageal carcinoma treated by LCAF radiotherapy.

Citation: Zhao KL, Wang Y, Shi XH. Late course accelerated hyperfractionated radiotherapy for clinical T_1-2 esophageal carcinoma. World J Gastroenterol 2003; 9(6): 1374-1376
URL: https://www.wjgnet.com/1007-9327/full/v9/i6/1374.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i6.1374